Mary Wilson
New member
Published: August 13, 2021
DOI: https://doi.org/10.1016/S1473-3099(21)00482-5
Luke B Snell, Penelope R Cli , Themoula Charalampous,
Adela Alcolea-Medina, Saidat A R T Ebie, Jasveen K Sehmi, Flavia Flaviani,
Rahul Batra, Sam T Douthwaite, Jonathan D Edgeworth, Gaia Nebbia
SARS-CoV-2 genome sequencing is embedded in academic and public health laboratories, but whether there are benefits to rapid sequencing in front-line hospital laboratories is unclear. We did rapid genome sequencing of SARS-CoV-2-positive nose and throat swabs from patients admitted to our hospital since July 7, 2021, to identify potential SARS-CoV-2 vaccine-escape variants for infection control and public health purposes. In addition, we did PCR-based genotyping of all new SARS-CoV-2 cases for three south London hospitals (Guy's and St Thomas', King's College, and Princess Royal University) using the AusDiagnostics SARS-CoV-2 Typing Panel (16-well) on the AusDiagnostics HighPlex, sequencing any non-typeable results.
We identified two cases of a potential vaccine-escape variant from the B.1.621 lineage. This variant of interest,[SUP]1[/SUP] first identified in Colombia, has lineage-associated spike mutations R346K, E484K, and P681H, which have been reported to show reduced neutralisation by antibodies.[SUP]2[/SUP][SUP], [/SUP] [SUP]3[/SUP][SUP], [/SUP] [SUP]4[/SUP] In addition, the variant we detected harbours a K417N spike mutation, which is associated with vaccine escape in the beta variant first identified in South Africa.[SUP]5[/SUP][SUP], [/SUP] [SUP]6
...
https://www.thelancet.com/action/showPdf?pii=S1473-3099%2821%2900482-5[/SUP]
DOI: https://doi.org/10.1016/S1473-3099(21)00482-5
Luke B Snell, Penelope R Cli , Themoula Charalampous,
Adela Alcolea-Medina, Saidat A R T Ebie, Jasveen K Sehmi, Flavia Flaviani,
Rahul Batra, Sam T Douthwaite, Jonathan D Edgeworth, Gaia Nebbia
SARS-CoV-2 genome sequencing is embedded in academic and public health laboratories, but whether there are benefits to rapid sequencing in front-line hospital laboratories is unclear. We did rapid genome sequencing of SARS-CoV-2-positive nose and throat swabs from patients admitted to our hospital since July 7, 2021, to identify potential SARS-CoV-2 vaccine-escape variants for infection control and public health purposes. In addition, we did PCR-based genotyping of all new SARS-CoV-2 cases for three south London hospitals (Guy's and St Thomas', King's College, and Princess Royal University) using the AusDiagnostics SARS-CoV-2 Typing Panel (16-well) on the AusDiagnostics HighPlex, sequencing any non-typeable results.
We identified two cases of a potential vaccine-escape variant from the B.1.621 lineage. This variant of interest,[SUP]1[/SUP] first identified in Colombia, has lineage-associated spike mutations R346K, E484K, and P681H, which have been reported to show reduced neutralisation by antibodies.[SUP]2[/SUP][SUP], [/SUP] [SUP]3[/SUP][SUP], [/SUP] [SUP]4[/SUP] In addition, the variant we detected harbours a K417N spike mutation, which is associated with vaccine escape in the beta variant first identified in South Africa.[SUP]5[/SUP][SUP], [/SUP] [SUP]6
...
https://www.thelancet.com/action/showPdf?pii=S1473-3099%2821%2900482-5[/SUP]